2017-2018流感季美国医保受益人接种流感疫苗后吉兰-巴雷综合征监测
近实时监测未信号提示接种后8-21天或1-42天GBS风险增加2.5倍;季末自我对照风险区间分析未发现所有季节疫苗合并、高剂量或标准剂量疫苗的GBS风险显著增加,但佐剂疫苗在8-21天风险升高(OR: 3.75; 95% CI: 1.01, 13.96),多重校正后无统计学意义(p=0.146)。
要点
- 近实时监测未信号提示2017-2018流感疫苗后GBS风险增加2.5倍
- 季末分析未发现所有季节疫苗合并、高剂量或标准剂量疫苗GBS风险显著增加
- 佐剂疫苗8-21天GBS风险OR 3.75(95%CI 1.01-13.96),多重校正后p=0.146
核心结论
- 多层监测方法未发现2017-2018流感疫苗接种后GBS风险增加。
- 佐剂疫苗8-21天GBS风险轻度升高但多重校正后无统计学意义,与所有美国许可流感疫苗说明书警示一致。
- 流感疫苗预防发病和死亡获益远大于潜在GBS风险。
研究设计与样本
- 对2017-2018流感季按服务收费医保受益人接种流感疫苗后GBS进行主动安全监测。
- 采用多层监测方法:季初近实时监测、与之前五个季节比较的更新序贯概率比检验(USPRT)、季末自我对照风险区间(SCRI)分析。
主要发现
- 近实时监测未信号提示接种后8-21天或1-42天GBS风险增加2.5倍。
- SCRI分析未发现≥65岁医保受益人接种所有季节疫苗合并、高剂量疫苗或标准剂量疫苗后8-21天或1-42天GBS风险显著增加。
- 佐剂疫苗接种后8-21天GBS风险OR为3.75(95% CI: 1.01, 13.96),多重校正后p=0.146。
临床怎么用
- 监测结果支持2017-2018流感季流感疫苗安全性,未发现GBS风险增加。
- 佐剂疫苗轻度GBS风险升高无统计学意义,与说明书警示一致,接种获益大于风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The U.S. Food and Drug Administration and the Centers for Medicare & Medicaid Services have been actively monitoring the risk of Guillain-Barré syndrome (GBS) following influenza vaccination among Fee-for-Service (FFS) Medicare beneficiaries every season since 2008. We present our evaluation of the GBS risk following influenza vaccinations during the 2017-2018 season. METHODS: We implemented a multilayered approach to active safety surveillance that included near real-time surveillance early in the season, comparing GBS rates post-vaccination during the 2017-2018 season with rates from five prior seasons using the Updating Sequential Probability Ratio Test (USPRT), and end-of-season self-controlled risk interval (SCRI) analyses. RESULTS: We identified approximately 16 million influenza vaccinations. The near real-time surveillance did not signal for a potential 2.5-fold increased GBS risk either in days 8-21 or 1-42 post-influenza vaccination. In the SCRI analyses, we did not detect statistically significant increased GBS risks among influenza-vaccinated Medicare beneficiaries ≥65 years for either the 8-21 or 1-42-day risk windows for all seasonal vaccines combined, high-dose vaccine, or standard-dose vaccines; we did detect an increased GBS risk in days 8-21 post-vaccination for individuals vaccinated with the adjuvanted vaccine (OR: 3.75; 95% CI: 1.01, 13.96), although this finding was not statistically significant after multiplicity adjustment (p = 0.146). CONCLUSIONS: Our multilayered surveillance approach-which allows for early detection of elevated GBS risk and provides reliable end-of-season SCRI estimates of effect size-did not identify an increased GBS risk following 2017-2018 influenza vaccinations. The slightly increased GBS risk with the adjuvanted vaccine, which was not statistically significant following multiplicity adjustment, is consistent with the package inserts of all U.S.-licensed influenza vaccines, which warn of a potential low increased GBS risk. The benefits of influenza vaccines in preventing morbidity and mortality heavily outweigh this potential risk.
引用
- Perez-Vilar S, Wernecke M, Arya D, et al. Surveillance for Guillain-Barré syndrome after influenza vaccination among U.S. Medicare beneficiaries during the 2017-2018 season. Vaccine. 2019. PMID: 31122853. doi:10.1016/j.vaccine.2019.05.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。